TYRATyra Biosciences, Inc.

$26.72

$10.2052 weeks$39.61

Price

$26.72+147%1Y

1M-0.45%1Y+147%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Below average

4/10

Value40

Quality27

Momentum70

Growth-

Strongest Momentum, weakest Quality · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

We are a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. Our in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help us design and predict which product candidates may demonstrate the highest potency, selectivity and tolerability in the clinic.

In the company’s own words · 10-K filed Mar 2, 2026 · SEC EDGAR

P/E (TTM)-

Market Cap$1.84B

1Y Return+147%

5Y Return-